Table 1.
(A) Baseline demographics for the cohort, (B) mpMRI outcomes, (C) biopsy outcomes and (D) diagnosis and treatment outcomes
| A. Patient demographics | |
| Men included | 112 |
| Median age (years) | 68 (IQR 62–78) |
| Median PSA (ng/mL) | 9.4 (IQR 5.6–21.0) |
| B. MpMRI outcomes | n | % |
| Men undertaking mpMRI | 111 | 99 |
| Median prostate volume (mL) | 50 (IQR 35–78) | |
| Positive mpMRI (men) | 87 | 78 |
| Negative mpMRI (men) | 24 | 22 |
| Total ROIs | 162 | |
| 1. ROIs/man | 39 | 35 |
| 2. ROIs/man | 25 | 23 |
| 3. ROIs/man | 22 | 20 |
| 4. ROIs/man | 1 | 1 |
| Likert score per man | ||
| Likert 3 | 25 | 23 |
| Likert 4 | 26 | 23 |
| Likert 5 | 36 | 32 |
| Total ROIs | 162 | |
| Median ROI volume (mL) | 0.5 (IQR 0.2–1.0) | |
| Likert score per lesion | ||
| Likert 3 | 71 | 44 |
| Likert 4 | 49 | 30 |
| Likert 5 | 42 | 26 |
| C. Biopsy outcomes | n | % | ||
| Men undertaking biopsy | 57 | 51 | ||
| Median cores per patient | 9 (IQR 5–12) | |||
| Total cores | 514 | |||
| Cores positive (UCL 2) | 241 | 47 | ||
| Biopsy efficiency | 47% | |||
| Median cores per lesion | 4 (IQR 4–5) | |||
| Median biopsy density (cores/ROI mL) | 10 (IQR 3.5–20) | |||
| Cancer detection by man | ||||
| Any cancer | 45 | 79 | ||
| UCL 2 | 43 | 75 | ||
| UCL 1 | 34 | 60 | ||
| Gleason ≥3+4 | 43 | 75 | ||
| Gleason ≥4+3 | 23 | 40 | ||
| Median MCCL (mm) | 7 (IQR 3–10) | |||
| Cancer detection by lesion | Any cancer | UCL 2 | UCL 1 | |
| Likert 3 (lesions biopsied) | 40 | 13 | 10 | 4 |
| Likert 4 (lesions biopsied) | 38 | 24 | 19 | 15 |
| Likert 5 (lesions biopsied) | 35 | 35 | 35 | 28 |
| D. Diagnosis and treatment outcomes | ||
| Median time to diagnosis (days) | 8 (IQR 5–12) | |
| Median time to treatment (days) | 20 (IQR 8–40) | |
| Treatment type (postbiopsy) | n | % |
| Discharged | 4 | 7 |
| PSA surveillance | 6 | 11 |
| Active surveillance | 5 | 9 |
| Focal therapy | 6 | 11 |
| Robotic prostatectomy | 9 | 16 |
| External beam radiotherapy | 10 | 18 |
| Brachytherapy | 2 | 4 |
| Androgen deprivation therapy | 9 | 16 |
| Chemotherapy | 4 | 7 |
| Antibiotics | 1 | 2 |
| Repeat biopsy | 1 | 2 |
MCCL, maximum cancer core length; mpMRI, multiparametric MRI; PSA, prostate-specific antigen; ROI, regions of interest; UCL, University College London.